Neumora Therapeutics (NMRA) Change in Acquisitions & Divestments (2022 - 2024)

Neumora Therapeutics' Change in Acquisitions & Divestments history runs 3 years deep, the most recent figure standing at $36.6 million for Q1 2024.

• On a quarterly basis, Change in Acquisitions & Divestments fell 17.5% year-over-year to $36.6 million in Q1 2024; TTM through Mar 2024 was $159.4 million, a N/A change from a year earlier, with the FY2023 full-year figure at $178.2 million, up 147.91% from the prior year.
• Change in Acquisitions & Divestments slipped to $36.6 million in Q1 2024 per NMRA's latest filing, from $38.4 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $44.3 million in Q1 2023 and bottomed at $36.6 million in Q1 2024.
• The 3-year median for Change in Acquisitions & Divestments is $39.2 million (2022), against an average of $39.8 million.
• Across the five-year window, Change in Acquisitions & Divestments slipped 4.25% in 2023 and dropped 17.5% in 2024, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $40.1 million in 2022, then decreased by 4.25% to $38.4 million in 2023, then slipped by 4.7% to $36.6 million in 2024.
• Per Business Quant, the three latest NMRA Change in Acquisitions & Divestments figures stand at $36.6 million (Q1 2024), $38.4 million (Q4 2023), and $44.3 million (Q1 2023).